Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infectedpatients

Journal of Infection and Chemotherapy

Volumn 18, Issue 4, 2012, Pages 587-590

  Di Biagio, Antonio ^a   Rosso, Raffaella ^a   Loregian, Arianna ^b   Pagni, Silvana ^b   Sormani, Maria Pia ^c   Cenderello, Giovanni ^d   Palù, Giorgio ^b   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d San Remo Hospital   (Italy)

Author keywords

Atazanavir; Hepatitis C virus (HCV) coinfection; Human immunodeficiency virus (HIV); Pharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; ATAZANAVIR PLUS RITONAVIR; BILIRUBIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG PLASMA TROUGH CONCENTRATION; FEMALE; HEPATITIS C; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERBILIRUBINEMIA; LIVER DYSFUNCTION; MALE; MIXED INFECTION; PILOT STUDY; SIDE EFFECT; VIREMIA;

EID: 84865115462     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-012-0402-y     Document Type: Article

References (15)

1. JM Alter 2006 Epidemiology of viral hepatitis and HIV co-infection J Hepatol 44 S6 S9 1635236310.1016/j.jhep.2005.11.004 (Pubitemid 43053865)
2. AH Mohsen 2002 Hepatitis C and HIV-1 coinfection Gut 51 601 608 12235089 10.1136/gut.51.4.6011:STN:280:DC%2BD38vntlSmsw%3D%3D
3. DL Thomas 2008 The challenge of hepatitis C in the HIV-infected person Annu Rev Med 59 473 485 1818670710.1146/annurev.med.59.081906.081110 1:CAS:528:DC%2BD1cXis12nu7s%3D (Pubitemid 351287950)
4. V Soriano M Puoti P Garcia-Gascó JK Rockstroh Y Benhamou P Barreiro, et al. 2008 Antiretroviral drugs and liverinjury AIDS 22 1 13 18090386 10.1097/QAD.0b013e3282f0e2fd (Pubitemid 350301936)
5. RA Branch 1998 Drugs in liver disease Clin Pharmacol Ther 64 462 464 9797803 10.1016/S0009-9236(98)90077-71:STN:280:DyaK1M%2FhsVGgtQ%3D%3D (Pubitemid 28473772)
6. DL Wyles JG Gerber 2005 Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction Clin Infect Dis 40174 181 15614709 10.1086/426021 1:CAS:528:DC%2BD2MXmslGruw%3D%3D (Pubitemid 40053477)
7. V Spagnuolo G Gentilini A De Bona L Galli C Uberti-Foppa A Soldarini, et al. 2007 Liver function parameters in HIV/HCVco-infected patients treated with amprenavir and ritonavir and correlation with plasma levels New Microbiol 30 279 28217802909 1:CAS:528:DC%2BD2sXhtVWnsr3N (Pubitemid 47264889)
8. E Seminari A De Bona G Gentilini L Galli G Schira N Gianotti, et al. 2007 Amprenavir and ritonavir plasmaconcentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment JAntimicrob Chemother 60 831 836 17684056 10.1093/jac/dkm282 1:CAS:528:DC%2BD2sXht1ygtbjL (Pubitemid 47434263)
9. P Barreiro S Rodríguez-Novoa P Labarga A Ruiz I Jiménez-Nácher L Martín-Carbonero, et al.2007 Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronichepatitis C J Infect Dis 195 973 979 17330787 10.1086/512086 1:CAS:528:DC%2BD2sXksVOlsbs%3D (Pubitemid 46452102)
10. M Regazzi P Villani R Gulminetti M Cusato M Brandolini C Tinelli, et al. 2011 Therapeutic monitoring and variabilityof atazanavir in HIV-infected patients, with and without HCV coinfection, receiving boosted or unboosted regimens Ther DrugMonit 33 303 308 21544015 10.1097/FTD.0b013e31821c2772 1:CAS:528:DC%2BC3MXlvFGmsLk%3D
11. C Aube F Oberti N Korali MA Namour D Loisel JY Tanguy, et al. 1999 Ultrasonographic diagnosis of hepatic fibrosis orcirrhosis J Hepatol 30 472 478 10190731 10.1016/S0168-8278(99)80107-X 1:STN:280:DyaK1M3gsFSjtA%3D%3D (Pubitemid 29113237)
12. A Loregian S Pagni E Ballarin E Sinigalia SG Parisi G Palù 2006 Simple determination of the HIV proteaseinhibitor atazanavir in human plasma by high-performance liquid chromatography with UV detection J Pharm Biomed Anal 42 500505 16765009 10.1016/j.jpba.2006.04.031 1:CAS:528:DC%2BD28Xps1Cis7g%3D (Pubitemid 44375103)
13. S Colombo T Buclin M Cavassini LA Décosterd A Telenti J Biollaz, et al. 2006 Population pharmacokinetics ofatazanavir in patients with human immunodeficiency virus infection Antimicrob Agents Chemother 50 3801 3808 1694006510.1128/AAC.00098-06 1:CAS:528:DC%2BD28XhtFOkt7nE (Pubitemid 44684896)
14. N von Hentig E Babacan T Lennemann G Knecht A Carlebach S Harder, et al. 2008 The steady-state pharmacokinetics ofatazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors J Antimicrob Chemother62 579 582 10.1093/jac/dkn204
15. S Rodríguez-Nóvoa J Morello P Barreiro I Maida P García-Gascó E Vispo, et al. 2008 Switchfrom ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring AIDS Res Hum Retrovir 24 821 82518507524 10.1089/aid.2007.0276 (Pubitemid 351871672)